Background: Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent licensing and availability of darunavir, etravirine and raltegravir has broadened management options available for highly treatment-experienced patients. However, data on their safety and efficacy in preventing vertical transmission are limited. Methods: A retrospective chart review of two cases describing obstetrical, infant and treatment outcomes associated with the use of regimens that include darunavir and etravirine with or without raltegravir during pregnancy was conducted. Results: We document two cases of pregnant HIVpositive women treated with antiretroviral therapy including darunavir, etravirine and raltegravir. Vertical transmission was averted and no congenital anomalies were observed. Conclusions: In the absence of human development toxicity data for these agents, these cases provide preliminary anecdotal data on their safety during pregnancy. Although the outcomes of these cases are reassuring, additional studies and registries are required to establish the safety and efficacy of these agents during pregnancy.
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Although antiretroviral therapy (ART) during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent licensing and availability of darunavir, etravirine and raltegravir has broadened management options available for highly treatment-experienced patients. However, pregnant women have been excluded in all major clinical trials of these agents and there is a lack of data describing their use in this context. The safety and efficacy of these more recently available antiretrovirals in preventing vertical transmission are therefore unknown.
Animal studies examining the potential for fetal toxicity with darunavir, etravirine or raltegravir have generally concluded that these agents would be developmentally safe, although there are hazards with extrapolating these data to humans [1] [2] [3] . For darunavir, a decrease in body weight gain and reductions in the numbers of ovulations and live fetuses were observed in animal studies [2] . Additional data describing the safety of newer antiretroviral agents is therefore required. We
Case report
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases Denise Jaworsky 1, 2 , Courtney Thompson 3 , Mark H Yudin 1, 4 , Ari Bitnun 1, 5 , Jason Brophy 3, 5, 6 , Lindy Samson 3, 6 , Tony Antoniou 7, 8 , Mona R Loutfy 1, 2 Introduction present two cases describing obstetrical, infant and treatment outcomes associated with the use of regimens including darunavir and etravirine with or without raltegravir during pregnancy.
Case 1
Case 1 was a 19-year-old HCV-coinfected woman diagnosed with HIV type-1 (HIV-1) infection at 3 years of age. She had previously been treated with multiple regimens, but had a history of poor adherence, contributing to genotypic resistance to all major classes of antiretrovirals and virological failure with an enfuvirtide-based regimen (Table 1) .
Lamivudine/zidovudine/abacavir (150/300/300 mg twice daily), tenofovir (300 mg once daily), etravirine (200 mg twice daily), darunavir (600 mg twice daily), ritonavir (100 mg twice daily) and raltegravir (400 mg twice daily) were initiated 21 weeks prior to conception. She continued on this regimen throughout pregnancy, with the exception of abacavir, which was discontinued 10 days following treatment initiation because of a clinically suspected hypersensitivity reaction. In addition to antiretrovirals, she was also receiving continuous treatment with sulfamethoxazole/trimethoprim and acyclovir, beginning at the time of conception. Other medications taken during various stages of the pregnancy included azithromycin, folic acid, iron, magnesium glucoheptonate and prenatal vitamin supplements. At 2 months following the initiation of ART, her viral load decreased from 185,719 to <50 copies/ml and remained at this level throughout pregnancy. In addition, her absolute CD4 + T-cell count increased from 0 to 450 cells/mm 3 at 16 months following the start of treatment. Antiretroviral adherence during pregnancy was generally good, although she reported occasional episodes of missed pills and a 3-week treatment interruption. At 40 weeks gestation, a 2.7 kg infant was spontaneously delivered.
All neonatal tests performed as part of the provincial (ON, Canada) metabolic screening were negative. Physical examination of the infant at birth and at 1 month revealed no dysmorphic features and no cardiac, respiratory or neurological abnormalities. With the exception of anaemia (nadir haemoglobin of 102 g/l at 8 weeks of age), the infant's laboratory indices remained normal. The infant's HIV-1 DNA PCR testing was negative at birth and at 2 months.
Case 2
Case 2 was a 17-year-old woman diagnosed with perinatally acquired HIV-1 infection at 9 months of age. She had a history of poor adherence and multiclass genotypic resistance (Table 1) . Prior to and at conception, she was receiving therapy with abacavir, lamivudine and lopinavir/ritonavir, but discontinued this regimen early in her pregnancy. At 4 months gestation, ART was initiated with lamivudine/zidovudine/abacavir (150/300/300 mg twice daily), tenofovir (300 mg once daily), etravirine (200 mg twice daily), darunavir (600 mg twice daily) and ritonavir (100 mg twice daily). At the time of conception, she was also receiving continuous therapy with monopril for essential hypertension, which was subsequently switched to amlodipine because of the toxicity of monopril in pregnancy. Other medication taken prenatally included cefotaxime and azithromycin for Streptococcus-pneumoniae-associated pneumonia and bacteraemia at 19 weeks gestation. Because of the late initiation of ART and ongoing or poor adherence during pregnancy, she agreed to hospital admission for directly observed treatment 2 weeks prior to delivery.
At 39 weeks gestation, she gave birth to a 3.2 kg infant by elective caesarean section, secondary to nonsuppression of viral load at the time of delivery. Viral load and CD4 + T-cell count at the time was 2,017 copies/ml and 372 cells/mm 3 , respectively. Physical examination of the infant at birth and subsequent visits revealed no congenital anomalies or significant metabolic abnormalities, although the infant had a falsepositive screen for congenital adrenal hyperplasia in the provincial (ON, Canada) neonatal metabolic screening programme. The infant developed anaemia by 3 weeks of age (nadir haemoglobin of 87 g/l at 5 weeks of age) and lactic acid was increased over the first 2 months (peak of 5.8 mmol/l at 2 weeks of age); both values normalized by 2 months. HIV-1 DNA PCR testing was negative at birth and at 4 months.
The clinical outcomes for the two cases are summarized in Table 2 .
Discussion
We have described two cases of pregnant women infected with HIV-1, who were treated with ART including darunavir, etravirine and raltegravir. Vertical transmission was averted and no congenital anomalies were observed.
In general, the regimens used for the prevention of maternal-fetal HIV transmission in these cases were well tolerated by the infants, resulting in toxicities that were reversible and amenable to close monitoring. Although anaemia was observed as a possible complication of therapy in both cases, this outcome was transient in nature and was likely associated with either maternal and/or infant use of zidovudine. Previous studies have found zidovudine to be associated with reversible anaemia in infants receiving prophylaxis in the antenatal, intrapartum and post-partum periods for vertical HIV transmission, and the use of this agent might explain the low haemoglobin values observed in these cases [4] [5] [6] . In addition, transient hyperlactataemia was observed in the infant described in case 2. Disruptions in lactate homeostasis have been observed in infants born to HIV-positive mothers who had taken nucleoside reverse transcriptase inhibitors during pregnancy, and in infants who had received post-exposure prophylactic treatment in the post-partum period. It is typically thought to be secondary to mitochondrial toxicity and is usually self-limited, resolving by 6 months, with no long-term complications to the infant [7] . We suspect that this is likely the case with the infant in case 2 as the lactic acidosis was an isolated finding with no other signs of mitochondrial toxicity. Finally, the infant in case 1 weighed 2.7 kg at birth, falling below the third percentile for infants born in Canada [8] . Although several retrospective studies have been unsuccessful in demonstrating an association between low birth weight and ART exposure during pregnancy, the possibility that the newer agents used in this case contributed to this outcome cannot be excluded [9] [10] [11] .
One limitation of this retrospective report is that pharmacokinetic drug levels of these newer agents in maternal and cord serum were not collected. Furthermore, more data on transplacental transfer of these newer agents in humans would be useful.
In the absence of human development toxicity data for these agents, these cases provide preliminary anecdotal data on their safety during pregnancy. Similar findings were reported in another report describing the use of darunavir, etravirine, enfuviritide, emtricitabine and tenofovir in a pregnant women initiating ART at 25 weeks gestation [12] . As our report is limited to two patients, additional studies and registries are required to establish the safety and efficacy of these newer agents during pregnancy. Additionally, whenever possible, pregnant women should be included in clinical trials of novel antiviral medications as this is a growing percentage of the HIV population. Their inclusion would be justified as there are existing pregnancy animal model data and data demonstrating safety in non-pregnant populations. As the number of women of reproductive age who are antiretroviral-experienced continues to grow, it is becoming increasingly important to collect scientifically rigourous data that will aid clinicians and patients in selecting effective regimens.
